The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Official Title: An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Study ID: NCT01120561
Brief Summary: This is a multicenter, open-label, single-arm, expanded access study designed to provide T-DM1 to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and efficacy of T-DM1 administered by intravenous (IV) infusion.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Investigational Site, Highland, California, United States
Investigational Site, Stockton, California, United States
Investigational Site, Denver, Colorado, United States
Investigational Site, Plantation, Florida, United States
Investigational Site, Lafayette, Indiana, United States
Investigational Site, Cedar Rapids, Iowa, United States
Investigational Site, Scarborough, Maine, United States
Investigational Site, Baltimore, Maryland, United States
Investigational Site, Detroit, Michigan, United States
Investigational Site, Clarkson Valley, Missouri, United States
Investigational Site, Farmington, New Mexico, United States
Investigational Site, Charlotte, North Carolina, United States
Investigational Site, Charleston, South Carolina, United States
Investigational Site, Fairfax, Virginia, United States
Investigational Site, Seattle, Washington, United States
Name: Clinical Trials
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR